Plus Therapeutics Awarded $17.6 Million from State of Texas
17 août 2022 17h46 HE
|
Plus Therapeutics Inc.
Funding from the Cancer Prevention and Research Institute of Texas (CPRIT), the second largest global public funder of cancer research, will support the majority of the development costs of 186RNL for...
Plus Therapeutics Announces Share Repurchase Program
15 août 2022 07h00 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and...
Plus Therapeutics Presents Positive Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases
13 août 2022 13h06 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, Aug. 13, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...
Plus Therapeutics to Present Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases
28 juil. 2022 07h00 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, July 28, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...
Plus Therapeutics to Present at Inaugural Targeted Radiopharmaceuticals Summit
27 juil. 2022 07h00 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...
Plus Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
21 juil. 2022 16h05 HE
|
Plus Therapeutics Inc.
Completed enrollment of Cohort 1 in ReSPECT-LM Phase 1/2a dose escalation trial of 186RNL for Leptomeningeal Metastases On track to complete key manufacturing objectives for cGMP 186RNL to support...
Plus Therapeutics to Announce Second Quarter 2022 Financial Results and Host Conference Call on July 21, 2022
13 juil. 2022 07h00 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, July 13, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...
Plus Therapeutics Successfully Completes Key Milestone for cGMP Manufacture of Lead Investigational Radiotherapeutic
12 juil. 2022 07h00 HE
|
Plus Therapeutics Inc.
Completes technology transfer and initiates cGMP manufacturing for critical Rhenium-186 NanoLiposome (186RNL) drug product intermediate On track to manufacture cGMP materials to support ongoing and...
Plus Therapeutics and Biocept Announce Comprehensive Laboratory Services Agreement for the ReSPECT-LM Trial
22 juin 2022 07h30 HE
|
Plus Therapeutics Inc.
Biocept’s CNSide™ assay provides a highly sensitive method to assess and quantify tumor cell burden in leptomeningeal metastasis (LM) of the central nervous system Assay results will be used to...
Plus Therapeutics Completes Enrollment of Cohort 1 ReSPECT-LM Phase 1/2a Trial
16 juin 2022 07h30 HE
|
Plus Therapeutics Inc.
Rhenium-186 NanoLiposome (186RNL) Targeted Radiotherapeutic successfully delivered without dose limiting toxicities in initial cohort Next step: Data Safety & Monitoring Board to consider further...